Liminal Biosciences

Liminal Biosciences
Last activity: 09.08.2021
Categories: BusinessHealthTechHumanProductResearchSpecialty
Liminal Biosciences Inc engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: Small molecule therapeutics and Plasma-derived therapeutics. The Small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The Plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.
Location: Canada, Laval
Employees: 201-500
Total raised: $105M
Founded date: 1994

Investors 3

Funding Rounds 1


Mentions in press and media 2

09.08.2021Liminal BioSciences : Announces Sale of Priority Review Vouc...LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMN...marketscre...
05.05.2021LIMINAL BIOSCIENCES INC. Liminal BioSciences : Notice of An...Notice of Annual and Special Meeting of Shareholders and Management Information Circular April 19,...marketscre...

Reviews 0

Sign up to leave a review

Sign up Log In